Merck Adds To Phase III Pipeline With Lundbeck Sleep-Aid Gaboxadol
Executive Summary
Merck's $270 mil. licensing deal for Lundbeck's Phase III sleep disorder agent gaboxadol could give Merck a fifth new product approval around the time that Zocor comes off patent
You may also be interested in...
Merck To Sign 50 Business Development Deals In 2005
Merck's goal is to sign about 50 business development deals in 2005, the same level as 2004, the company said
Merck To Sign 50 Business Development Deals In 2005
Merck's goal is to sign about 50 business development deals in 2005, the same level as 2004, the company said
Pfizer/Neurocrine File First Indiplon NDA With Eye On Q4 2005 Launch
The first of two NDA filings for Pfizer/Neurocrine's insomnia agent indiplon puts the drug on track for a launch in the fourth quarter of 2005